Molecular structure of MCI-186, CAS Number: 89-25-8
MCI-186 (CAS 89-25-8)
See product citations (10)
Alternate Names:
3-Methyl-1-phenyl-2-pyrazolin-5-one; Edaravone; NSC 2629
Application:
MCI-186 is a free radical scavenger that enhances NGF protein levels via the JNK pathway
CAS Number:
89-25-8
Purity:
≥98%
Molecular Weight:
174.20
Molecular Formula:
C10H10N2O
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
MCI-186, also known as 3-methyl-1-phenyl-2-pyrazolin-5-one, is a free radical scavenger that may act to contain protective properties towards murine brain ischemia. In vitro this compound has been reported to decrease cell death in murine models. Mechanistic studies suggest that MCI-186 enhances neuronal growth factor (NGF) protein levels which are essential for neuronal growth and survival. Furthermore, the enhancement of NGF expression in astrocytes has been thought to be done via the c-Jun N-terminal Kinase (JNK) pathway.
MCI-186 (CAS 89-25-8) References
- MCI-186 (edaravone), a novel free radical scavenger, protects against acute autoimmune myocarditis in rats. | Nimata, M., et al. 2005. Am J Physiol Heart Circ Physiol. 289: H2514-8. PMID: 16100244
- MCI-186 prevents brain tissue from neuronal damage in cerebral infarction through the activation of intracellular signaling. | Niyaz, M., et al. 2007. J Neurosci Res. 85: 2933-42. PMID: 17628025
- Edaravone reduces brain oedema and attenuates cell death after intracerebral haemorrhage in mice. | Zhou, F., et al. 2009. Brain Inj. 23: 353-7. PMID: 19330597
- Edaravone, a free radical scavenger, protects components of the neurovascular unit against oxidative stress in vitro. | Lee, BJ., et al. 2010. Brain Res. 1307: 22-7. PMID: 19840779
- Edaravone improves the expression of nerve growth factor in human astrocytes subjected to hypoxia/reoxygenation. | Yoshida, H., et al. 2010. Neurosci Res. 66: 284-9. PMID: 19954754
- Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. | Abe, K., et al. 2014. Amyotroph Lateral Scler Frontotemporal Degener. 15: 610-7. PMID: 25286015
- Edaravone: A new drug approved for ALS. | Rothstein, JD. 2017. Cell. 171: 725. PMID: 29100067
- Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. | Jaiswal, MK. 2019. Med Res Rev. 39: 733-748. PMID: 30101496
- Amyotrophic Lateral Sclerosis: An Update for 2018. | Oskarsson, B., et al. 2018. Mayo Clin Proc. 93: 1617-1628. PMID: 30401437
- A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed? | Xu, X., et al. 2021. Transl Neurodegener. 10: 29. PMID: 34372914
- Edaravone ameliorates depressive and anxiety-like behaviors via Sirt1/Nrf2/HO-1/Gpx4 pathway. | Dang, R., et al. 2022. J Neuroinflammation. 19: 41. PMID: 35130906
- Comprehensive Research on Past and Future Therapeutic Strategies Devoted to Treatment of Amyotrophic Lateral Sclerosis. | Sever, B., et al. 2022. Int J Mol Sci. 23: PMID: 35269543
- Clinical studies in amyotrophic lateral sclerosis. | Dorst, J. and Genge, A. 2022. Curr Opin Neurol. 35: 686-692. PMID: 35942672
- Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents. | Johnson, SA., et al. 2022. Drugs. 82: 1367-1388. PMID: 36121612
- Effects of a novel free radical scavenger, MCl-186, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. | Kawai, H., et al. 1997. J Pharmacol Exp Ther. 281: 921-7. PMID: 9152402
Inhibitor of:
Apoptosis, gp91-phox, MPV17L, Nitrotyrosine, p47-phox, SCARF (scavenger receptor class F), and SOD-1.Activator of:
XEDAR.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MCI-186, 5 g | sc-200806 | 5 g | $20.00 | |||
MCI-186, 100 g | sc-200806A | 100 g | $32.00 |